Microdosed GLP-1 Peptides
The future of GLP-1.
Explore microdosed GLP-1 receptor agonists, precision stacks, and personalized protocols. Evidence-based research for the modern biohacker.
The Science
How microdosing GLP-1 works
Instead of taking a full dose, microdosing uses a much smaller amount of GLP-1. This gives your body the benefits, like less hunger and better metabolism, without the harsh side effects.
Gentle Activation
A small dose connects with your body's natural GLP-1 receptors, the same ones that control hunger, blood sugar, and energy, without overwhelming your system.
Signals Your Body
Once activated, your cells start sending signals that help you feel full sooner, use sugar more efficiently, and keep your energy steady throughout the day.
Your Body Adapts
Over a few weeks, your metabolism starts working better on its own. You burn more fat, crave less junk food, and your blood sugar stays more stable.
Lasting Results
With consistent use, the benefits stick around. You naturally eat less, maintain a healthier weight, and feel more energized without the yo-yo effect.
Most microdosing protocols use about 10–25% of a standard dose, taken on a regular schedule. This keeps the benefits going while avoiding common side effects like nausea.
Find your optimal protocolOur Philosophy
We believe everyone benefits from microdosing GLP-1
Whether you're looking to manage your weight, boost your energy, or simply feel better in your body, microdosed GLP-1 can help. It's not just for extreme cases. It's for anyone who wants to take control of their health, gently and effectively.
Explore GLP-1 library
For Him & Her
Designed for those who refuse to age on schedule
Metabolic Health
Metabolic Rejuvenation
Body Composition
Optimized Physique
The Science
Built on incretin precision
Each GLP-1 compound in our library is backed by peer-reviewed research and clinical trial data. We compile mechanism-of-action profiles, pharmacokinetic data, and dosing protocols from published studies.
View GLP-1 protocolsGLP-1 Library
Featured GLP-1 compounds
Semaglutide
A GLP-1 receptor agonist engineered with a C-18 fatty acid chain for albumin binding, extending its half life to approximately 7 days. The most widely studied incretin mimetic for weight management and metabolic optimization.
Tirzepatide
A dual GIP/GLP-1 receptor agonist representing the next evolution in incretin therapy. Simultaneously activates both incretin receptors for superior metabolic outcomes compared to selective GLP-1 agonists.
Liraglutide
A first generation GLP-1 receptor agonist with 97% homology to native GLP-1. Features a C-16 fatty acid enabling albumin binding for once daily dosing. Established long term safety profile spanning over a decade of clinical use.
Dulaglutide
A GLP-1 receptor agonist fused to a modified IgG4 Fc fragment, creating a large molecule with extended pharmacokinetics. Designed for once weekly administration with consistent plasma levels.
Exenatide
A synthetic version of exendin-4, originally isolated from Gila monster saliva. The first GLP-1 receptor agonist approved for clinical use, sharing 53% sequence homology with human GLP-1 while resisting DPP-4 degradation.
Lixisenatide
A modified exendin-4 analog with six additional lysine residues at the C-terminus. Primarily targets postprandial glucose excursions through potent gastric emptying delay.
Interactive Tool
Not sure where to start?
Our Protocol Finder analyzes your research goals, experience level, and preferences to recommend the optimal GLP-1 protocol.
Common Questions